Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.
about
Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.Current development and future prospects in chemotherapy of tuberculosisPromising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine modelSuccessful Treatment of Disseminated Bacillus Calmette-Guérin Disease in an HIV-Infected Child with a Linezolid-Containing Regimen.Multidrug-resistant tuberculosis: a review of the 23 cases treated by the Saint-Pierre University Hospital (Brussels).Fighting tuberculosis: old drugs, new formulations.Development of new antituberculous agents based on new drug targets and structure-activity relationship.Novel conjugate of moxifloxacin and carboxymethylated glucan with enhanced activity against Mycobacterium tuberculosis.Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis.Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.A Stability-Indicating High Performance Liquid Chromatographic Assay for the Simultaneous Determination of Pyridoxine, Ethionamide, and Moxifloxacin in Fixed Dose Combination Tablets
P2860
Q30498213-A8F301ED-BFB5-4F1F-9AE0-2977C8E5B948Q35127770-9325413A-B68D-4568-809F-E93524026D9BQ35705874-8D368BB2-4AAA-4142-A464-F32C046AAB6EQ37144892-32B6AC98-2048-4100-82A2-3A17092794CFQ37359729-71923A84-85F1-49C9-86EF-BAB6D2021C2FQ37477066-8D4EDC47-BCCB-40F5-8ABA-1DE572DC0678Q37579212-58227195-95E1-4AAD-BF36-11FF2276ADD7Q40138610-2191CAB4-FE5A-4AAA-B617-BEE487DF10D6Q40275630-B4481E75-11D0-4C97-AF23-CA2CAD6DF3D4Q41901445-1F15EEC9-4EB2-4FE4-BF43-B235544560E6Q45972156-A0B75159-9B57-435C-A05B-9B6EE1BA5911Q46514177-CC835545-88C3-4B0D-B94B-737D8C9D65CBQ59036768-50782855-7849-4FE1-954F-072F551F0D98
P2860
Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Activities of moxifloxacin alo ...... osis infection in BALB/c mice.
@en
Activities of moxifloxacin alo ...... osis infection in BALB/c mice.
@nl
type
label
Activities of moxifloxacin alo ...... osis infection in BALB/c mice.
@en
Activities of moxifloxacin alo ...... osis infection in BALB/c mice.
@nl
prefLabel
Activities of moxifloxacin alo ...... osis infection in BALB/c mice.
@en
Activities of moxifloxacin alo ...... osis infection in BALB/c mice.
@nl
P2093
P2860
P1476
Activities of moxifloxacin alo ...... losis infection in BALB/c mice
@en
P2093
Dejiang Tan
Elisabetta Iona
Federico Giannoni
Graziella Orefici
Lara Brunori
Simona Recchia
P2860
P304
P356
10.1128/AAC.47.1.360-362.2003
P407
P577
2003-01-01T00:00:00Z